NCT06706791 Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
| NCT ID | NCT06706791 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Fazaia Ruth Pfau Medical College |
| Condition | Chronic Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 156 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 156 participants in total. It began in 2025-04-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Effect of Empagliflozin on Quality of Life in patient of Chronic Heart Failure with Diabetes Mellitus Type II. As per ESC Guidelines Empagliflozin is recommended as part of the first-line treatment for HFrEF, irrespective of diabetes status. As per American College of Cardiology (ACC)/American Heart Association (AHA) Empagliflozin is recommended in both diabetic and non-diabetic HF (especially beneficial in patients with HFrEF and HFpEF). The aim of my study is to assess the impact of Empagliflozin on quality of life in Pakistani patients, considering the genetic, environmental and cultural factors. The study will also explore whether Empagliflozin can offer cost-effective option for managing chronic heart failure and diabetes, potentially reducing the economic burden on both patients and health care system.
Eligibility Criteria
Inclusion Criteria: 1. Age 40-70 years at time of screening. 2. Both Men and women are included in study. 3. Patients with chronic heart failure and currently categorized in class II-IV heart failure as per NHYA classification having ejection fraction less than 40%. 4. Patients having NT- proBNP levels greater than 25pg/ml. 5. Diabetic patient diagnosed (HbA1c \> 6.5mg/dl) and currently taking antidiabetic medicine. Exclusion Criteria: 1. Pregnant female. 2. Patient with end stage renal disease (ESRD). 3. Patient with acute decompensated heart failure. 4. Acute coronary syndrome patients.
Contact & Investigator
Tooba Riaz, MBBS
PRINCIPAL INVESTIGATOR
Fazaia Ruth Pfau Medical College
Frequently Asked Questions
Who can join the NCT06706791 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 70 Years, studying Chronic Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06706791 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06706791 currently recruiting?
Yes, NCT06706791 is actively recruiting participants. Contact the research team at drtoobariaz@outlook.com for enrollment information.
Where is the NCT06706791 trial being conducted?
This trial is being conducted at Karachi, Pakistan.
Who is sponsoring the NCT06706791 clinical trial?
NCT06706791 is sponsored by Fazaia Ruth Pfau Medical College. The principal investigator is Tooba Riaz, MBBS at Fazaia Ruth Pfau Medical College. The trial plans to enroll 156 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.